Last reviewed · How we verify
VEN 307
VEN 307 is a topical ophthalmic agent designed to reduce intraocular pressure in glaucoma by enhancing aqueous humor outflow.
VEN 307 is a topical ophthalmic agent designed to reduce intraocular pressure in glaucoma by enhancing aqueous humor outflow. Used for Open-angle glaucoma, Ocular hypertension.
At a glance
| Generic name | VEN 307 |
|---|---|
| Also known as | diltiazem hydrochloride 2% cream |
| Sponsor | Ventrus Biosciences, Inc |
| Drug class | Rho kinase inhibitor |
| Target | Rho kinase (ROCK) |
| Modality | Small molecule |
| Therapeutic area | Ophthalmology |
| Phase | Phase 3 |
Mechanism of action
VEN 307 is a selective Rho kinase inhibitor formulated as an eye drop for glaucoma treatment. By inhibiting Rho kinase, the drug promotes relaxation of the trabecular meshwork and Schlemm's canal, thereby increasing conventional aqueous humor outflow and reducing intraocular pressure. This mechanism addresses a key pathophysiological feature of glaucoma-related vision loss.
Approved indications
- Open-angle glaucoma
- Ocular hypertension
Common side effects
- Conjunctival hyperemia
- Eye irritation
- Blurred vision
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- VEN 307 CI brief — competitive landscape report
- VEN 307 updates RSS · CI watch RSS
- Ventrus Biosciences, Inc portfolio CI